Application of Radiomics in Prognosing Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Systematic Review and Meta-Analysis

Ting Wei Wang; Ming Sheng Hsu; Yi Hui Lin; Hwa Yen Chiu; Heng Sheng Chao; Chien Yi Liao; Chia Feng Lu; Yu Te Wu; Jing Wen Huang; Yuh Min Chen

doi:10.3390/cancers15143542

Application of Radiomics in Prognosing Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Systematic Review and Meta-Analysis

Ting Wei Wang, Ming Sheng Hsu, Yi Hui Lin, Hwa Yen Chiu, Heng Sheng Chao, Chien Yi Liao, Chia Feng Lu, Yu Te Wu, Jing Wen Huang^*, Yuh Min Chen^*

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

3 Scopus citations

Abstract

In the context of non-small cell lung cancer (NSCLC) patients treated with EGFR tyrosine kinase inhibitors (TKIs), this research evaluated the prognostic value of CT-based radiomics. A comprehensive systematic review and meta-analysis of studies up to April 2023, which included 3111 patients, was conducted. We utilized the Quality in Prognosis Studies (QUIPS) tool and radiomics quality scoring (RQS) system to assess the quality of the included studies. Our analysis revealed a pooled hazard ratio for progression-free survival of 2.80 (95% confidence interval: 1.87–4.19), suggesting that patients with certain radiomics features had a significantly higher risk of disease progression. Additionally, we calculated the pooled Harrell’s concordance index and area under the curve (AUC) values of 0.71 and 0.73, respectively, indicating good predictive performance of radiomics. Despite these promising results, further studies with consistent and robust protocols are needed to confirm the prognostic role of radiomics in NSCLC.

Original language	English
Article number	3542
Journal	Cancers
Volume	15
Issue number	14
DOIs	https://doi.org/10.3390/cancers15143542
State	Published - Jul 2023

Keywords

computed tomography
EGFR tyrosine kinase inhibitors
non-small cell lung cancer
radiomics
treatment outcome

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/cancers15143542

Cite this

@article{711e97278f1a48f78a92a6705a59407e,

title = "Application of Radiomics in Prognosing Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Systematic Review and Meta-Analysis",

abstract = "In the context of non-small cell lung cancer (NSCLC) patients treated with EGFR tyrosine kinase inhibitors (TKIs), this research evaluated the prognostic value of CT-based radiomics. A comprehensive systematic review and meta-analysis of studies up to April 2023, which included 3111 patients, was conducted. We utilized the Quality in Prognosis Studies (QUIPS) tool and radiomics quality scoring (RQS) system to assess the quality of the included studies. Our analysis revealed a pooled hazard ratio for progression-free survival of 2.80 (95% confidence interval: 1.87–4.19), suggesting that patients with certain radiomics features had a significantly higher risk of disease progression. Additionally, we calculated the pooled Harrell{\textquoteright}s concordance index and area under the curve (AUC) values of 0.71 and 0.73, respectively, indicating good predictive performance of radiomics. Despite these promising results, further studies with consistent and robust protocols are needed to confirm the prognostic role of radiomics in NSCLC.",

keywords = "computed tomography, EGFR tyrosine kinase inhibitors, non-small cell lung cancer, radiomics, treatment outcome",

author = "Wang, {Ting Wei} and Hsu, {Ming Sheng} and Lin, {Yi Hui} and Chiu, {Hwa Yen} and Chao, {Heng Sheng} and Liao, {Chien Yi} and Lu, {Chia Feng} and Wu, {Yu Te} and Huang, {Jing Wen} and Chen, {Yuh Min}",

note = "Publisher Copyright: {\textcopyright} 2023 by the authors.",

year = "2023",

month = jul,

doi = "10.3390/cancers15143542",

language = "English",

volume = "15",

journal = "Cancers",

issn = "2072-6694",

publisher = "Multidisciplinary Digital Publishing Institute",

number = "14",

}

TY - JOUR

T1 - Application of Radiomics in Prognosing Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

T2 - A Systematic Review and Meta-Analysis

AU - Wang, Ting Wei

AU - Hsu, Ming Sheng

AU - Lin, Yi Hui

AU - Chiu, Hwa Yen

AU - Chao, Heng Sheng

AU - Liao, Chien Yi

AU - Lu, Chia Feng

AU - Wu, Yu Te

AU - Huang, Jing Wen

AU - Chen, Yuh Min

PY - 2023/7

Y1 - 2023/7

N2 - In the context of non-small cell lung cancer (NSCLC) patients treated with EGFR tyrosine kinase inhibitors (TKIs), this research evaluated the prognostic value of CT-based radiomics. A comprehensive systematic review and meta-analysis of studies up to April 2023, which included 3111 patients, was conducted. We utilized the Quality in Prognosis Studies (QUIPS) tool and radiomics quality scoring (RQS) system to assess the quality of the included studies. Our analysis revealed a pooled hazard ratio for progression-free survival of 2.80 (95% confidence interval: 1.87–4.19), suggesting that patients with certain radiomics features had a significantly higher risk of disease progression. Additionally, we calculated the pooled Harrell’s concordance index and area under the curve (AUC) values of 0.71 and 0.73, respectively, indicating good predictive performance of radiomics. Despite these promising results, further studies with consistent and robust protocols are needed to confirm the prognostic role of radiomics in NSCLC.

AB - In the context of non-small cell lung cancer (NSCLC) patients treated with EGFR tyrosine kinase inhibitors (TKIs), this research evaluated the prognostic value of CT-based radiomics. A comprehensive systematic review and meta-analysis of studies up to April 2023, which included 3111 patients, was conducted. We utilized the Quality in Prognosis Studies (QUIPS) tool and radiomics quality scoring (RQS) system to assess the quality of the included studies. Our analysis revealed a pooled hazard ratio for progression-free survival of 2.80 (95% confidence interval: 1.87–4.19), suggesting that patients with certain radiomics features had a significantly higher risk of disease progression. Additionally, we calculated the pooled Harrell’s concordance index and area under the curve (AUC) values of 0.71 and 0.73, respectively, indicating good predictive performance of radiomics. Despite these promising results, further studies with consistent and robust protocols are needed to confirm the prognostic role of radiomics in NSCLC.

KW - computed tomography

KW - EGFR tyrosine kinase inhibitors

KW - non-small cell lung cancer

KW - radiomics

KW - treatment outcome

UR - http://www.scopus.com/inward/record.url?scp=85167864742&partnerID=8YFLogxK

U2 - 10.3390/cancers15143542

DO - 10.3390/cancers15143542

M3 - Review article

AN - SCOPUS:85167864742

SN - 2072-6694

VL - 15

JO - Cancers

JF - Cancers

IS - 14

M1 - 3542

ER -

Application of Radiomics in Prognosing Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Systematic Review and Meta-Analysis

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this